GILD hit a rough patch, but analysts aren’t convinced it’s a bargain
Biopharma has been among the market’s most debated sectors lately. While major breakthroughs and active pipelines have fueled optimism, financial results haven’t always kept pace.
One name that has been bouncing between momentum and skepticism a lot is Gilead Sciences, which recently experienced a pullback that has investors digging deeper into the underlying data.
Understanding the variables
Gilead’s current setup includes a mix of stability, risk, and an ongoing transition. On the surface, the latest financials look solid:
- $29 billion in annual revenue marks a 2.4% growth rate
- A strong operating margin near 40% beats many rivals
- Balance sheet highlights include low debt-to-equity and solid cash levels
GILD shares are trading around 20-21x earnings, which Wall Street agrees is a reasonable level, even if the stock isn’t exactly cheap. And shares clawed back much of the previous few days’ losses during Tuesday’s session, adding more than 2% for the day.
A number of encouraging factors are supporting the bullish outlook, including Gilead’s impressive market share for key HIV drugs, its expansion into oncology and liver disease, and upcoming FDA decisions that could unlock new growth streams.
And with no major patent cliffs for another decade, revenue forecasts may be more reliable than some of its major competitors.
But more than a few headwinds are holding the company back. A number of legacy drugs are facing renewed competition and price pressure as COVID-era revenue continues to decline.
Some analysts are also wary of heavy spending, such as the company’s $7.8 billion Arcellx deal.
Wall Street is making its bets
Historically, Gilead has performed relatively well through downturns, typically falling less and recovering more steadily than the broader market. So, with GILD stock currently near the lower end of its recent trading range, the prevailing sentiment among analysts is that it’s not time to throw in the towel on the company just yet. A recent EPS and 2.4% dividend yield further
With the majority of institutions tracking Gilead giving it a “buy” rating and institutional ownership sitting around 84%, big money is still interested. A consensus price target of around $157 doesn’t predict rocketship gains from here, but it does imply modest upside potential vs. recent levels in the high $130s.
A recent EPS beat and 2.4% dividend yield also boosted the company’s long-term stability.
More signs of cautious optimism comes from shops like Ameriprise and Invesco, which have been aggressively adding shares. However, roughly $42 million in recent insider selling has raised a few eyebrows among market watchers.
When it comes to finding value, stock price is just one of several important considerations. Institutions are still willing to increase their stake in Gilead for now, but they’re waiting for tangible evidence that the company’s transition narrative can drive the next leg of growth.